The biggest pharma deal of the year might be coming from Mumbai.
Sun Pharmaceutical Industries - India's largest drug maker - sent a binding $12 billion offer for Organon on April 10 after three months of due diligence, with JPMorgan and MUFG backing the financing.
Organon shares jumped about 23% on Friday, the stock's best single-day gain ever, adding billions in market value to a company that had been trading under $7 just weeks earlier.
Sun Pharma's stock went the other way, falling more than 3% in Mumbai as investors worried about the debt needed to close a deal this size. This is a pattern acquirers often see - the target jumps while the buyer dips as the market weighs the near-term cost of the deal against the long-term benefit.
The deal would give Sun Pharma a front-end commercial operation in the United States along with a portfolio of branded products in women's health, biosimilars - near-copies of expensive biologic drugs sold at lower prices - and established medicines.
That fills a gap for a company that has mostly competed in specialty and generic drugs and has wanted a stronger foothold in the U.S. market for years. Building a commercial platform from scratch in the U.S. takes years and costs billions, so buying one is faster.
Organon's product lineup includes Nexplanon, one of the most widely used birth control implants in the world, along with a growing biosimilars business that brought in more than $1 billion in revenue last year. The company also sells established brands like NuvaRing and has a pipeline of reproductive health products in development.
Organon was spun off from Merck in 2021 and has been focused on women's health as its core growth driver since, building out a commercial team and product portfolio aimed at an underserved market. The global women's health market is expected to grow at more than 5% annually over the next decade.
If the deal goes through, it would be the largest overseas buy in Indian pharma history, topping Sun Pharma's own 2014 acquisition of Ranbaxy for $4 billion. It would also make Sun Pharma one of the top 20 pharmaceutical companies in the world by revenue.
The deal comes at a time when Indian pharma companies are increasingly looking to acquire established brands abroad rather than compete purely on generic pricing.
Cipla, Dr. Reddy's, and Lupin have all made smaller U.S. acquisitions in the past two years, but none close to Sun Pharma's $12 billion bid.
The spread between the offer price and where Organon trades will tell you how likely the market thinks this deal is to close. Sun Pharma still needs to lock down financing, clear regulatory reviews in multiple countries, and convince its own shareholders that the debt load is worth it.
Antitrust review in the U.S. could take several months given the overlap in biosimilar products, and any competing bid from another pharma company would change the math entirely for both sides.
Investors holding Organon should watch for a formal regulatory filing timeline, which would signal how quickly Sun Pharma expects to close.
